The NIH spent the majority of its money on broader, observational research that won't directly bring relief to patients.
 Mike Reddy for STAT
The NIH has poured $1 billion into long Covid research — with little to show for it A STAT and MuckRock investigation shows the NIH hasn't picked up the pace on its long Covid research. Instead, the delays have compounded. The NIH hasn't signed up a single patient to test any potential treatments — despite a clear mandate from Congress to study them. Read more. By Rachel Cohrs and Betsy Ladyzhets |
|
 Mike Belleme for STAT
In a town plagued by an environmental crisis, a local abortion debate consumes public attention In the town of Bristol, Tenn., the anti-landfill activists and the anti-abortion activists seem to live in different worlds. They are, in very different registers, each asking who should have control over other people's bodies. Read more. By Eric Boodman
 Maddie McGarvey for STAT
A bellwether moment: Once a distant dream, gene therapy for Duchenne nears historic decision The looming FDA decision on Sarepta's gene therapy for Duchenne muscular dystrophy has made this perhaps the most consequential moment in the history of one of the most common and debilitating rare diseases — the culmination of 40 years of work by patient advocates, research groups, and rival companies racing on two continents. Read more. By Jason Mast and Adam Feuerstein
More great reads from STAT this week |
|
Check out more exclusive coverage with a STAT+ subscription | Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles. |
|
| STAT, 1 Exchange Place, Boston, MA | ©2023, All Rights Reserved. | |
|
No comments